806 results

Mechanisms of drug resistance in breast cancer liver metastases: Dilemmas and opportunities

Chun-Yan Yan; Meng-Lu Zhao; Ya-Nan Wei et al.

Molecular Therapy: Oncolytics, Vol. 28 · 2023 · English · DOAJ

Breast cancer is the leading cause of cancer-related deaths in females worldwide, and the liver is one of the most common sites of distant metastases in breast cancer patients. Patients with breast cancer liver metastases face limited treatment options, and drug resistance is highly prevalent…

Radiovirotherapy at twenty

David Dingli

Molecular Therapy: Oncolytics, Vol. 29 · 2023 · English · DOAJ

Current advances of liquid biopsies in prostate cancer: Molecular biomarkers

Murad Alahdal; Roshane A. Perera; Marcio Covas Moschovas et al.

Molecular Therapy: Oncolytics, Vol. 30 · 2023 · English · DOAJ

Prostate cancer (PCa) incidence is increasing and endangers men’s lives. Early detection of PCa could improve overall survival (OS) by preventing metastasis. The prostate-specific antigen (PSA) test is a popular screening method. Several advisory groups, however, warn against using the PSA test due…

Smoking induces WEE1 expression to promote docetaxel resistance in esophageal adenocarcinoma

Md Obaidul Islam; Krishnapriya Thangaretnam; Heng Lu et al.

Molecular Therapy: Oncolytics, Vol. 30 · 2023 · English · DOAJ

Esophageal adenocarcinoma (EAC) patients have poor clinical outcomes, with an overall 5-year survival rate of 20%. Smoking is a significant risk factor for EAC. The role of WEE1, a nuclear kinase that negatively regulates the cell cycle in normal conditions, in EAC tumorigenesis and drug resistance…

Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells

Matthew Holmes; Gina B. Scott; Samuel Heaton et al.

Molecular Therapy: Oncolytics, Vol. 29 · 2023 · English · DOAJ

Primary drug resistance and minimal residual disease are major challenges in the treatment of B cell neoplasms. Therefore, this study aimed to identify a novel treatment capable of eradicating malignant B cells and drug-resistant disease. Oncolytic viruses eradicate malignant cells by direct…

Polycytidine tract deletion from microRNA-detargeted oncolytic Mengovirus optimizes the therapeutic index in a murine multiple myeloma model

Velia Penza; Justin W. Maroun; Rebecca A. Nace et al.

Molecular Therapy: Oncolytics, Vol. 28 · 2023 · English · DOAJ

Mengovirus is an oncolytic picornavirus whose broad host range allows for testing in immunocompetent cancer models. Two pathogenicity-ablating approaches, polycytidine (polyC) tract truncation and microRNA (miRNA) targets insertion, eliminated the risk of encephalomyocarditis. To investigate…

Expanding the landscape of TCR gene therapy targeting MAGE

Zhiyuan Mao; John K. Lee

Molecular Therapy: Oncolytics, Vol. 29 · 2023 · English · DOAJ

Sodium iodide symporter-targeted gene therapy in glioblastoma

Juan Pablo Nicola; Christopher J. LaRocca

Molecular Therapy: Oncolytics, Vol. 28 · 2023 · English · DOAJ

oHSV-P10 reduces glioma stem cell enrichment after oncolytic HSV therapy

Upasana Sahu; Matthew P. Mullarkey; Guangsheng Pei et al.

Molecular Therapy: Oncolytics, Vol. 29 · 2023 · English · DOAJ

Longstanding evidence implicate glioma stem-like cells as the main drivers contributing toward glioblastoma (GBM) therapy resistance and tumor recurrence. Although oncolytic herpes simplex virus (oHSV) viral therapy is a promising biological therapy recently approved for melanoma (in the United…

Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T

Li Shiqi; Zhang Jiasi; Chen Lvzhe et al.

Molecular Therapy: Oncolytics, Vol. 29 · 2023 · English · DOAJ

CD19-targeted chimeric antigen receptor T lymphocytes (CAR-T) has demonstrated a high proportion of complete remission in the treatment of relapsed refractory acute B cell lymphoblastic leukemia (r/r B-ALL). It is of great clinical significance to explore which factors will impact long-term…

Vaccinia virus and peptide-receptor radiotherapy synergize to improve treatment of peritoneal carcinomatosis

Kathryn Ottolino-Perry; David Mealiea; Clara Sellers et al.

Molecular Therapy: Oncolytics, Vol. 29 · 2023 · English · DOAJ

Tumor-specific overexpression of receptors enables a variety of targeted cancer therapies, exemplified by peptide-receptor radiotherapy (PRRT) for somatostatin receptor (SSTR)-positive neuroendocrine tumors. While effective, PRRT is restricted to tumors with SSTR overexpression. To overcome this…

Characterization and quantitation of busulfan DNA adducts in the blood of patients receiving busulfan therapy

Valeria Guidolin; Yupeng Li; Foster C. Jacobs et al.

Molecular Therapy: Oncolytics, Vol. 28 · 2023 · English · DOAJ

DNA alkylating drugs have been used as cancer chemotherapy with variable outcomes. The establishment of predictive biomarkers to identify patients who will effectively respond to treatment would allow for the development of personalized therapies. As the degree of interaction of alkylating drug…

Ligand-based, piggyBac-engineered CAR-T cells targeting EGFR are safe and effective against non-small cell lung cancers

Thanyavi Chinsuwan; Koichi Hirabayashi; Shuji Mishima et al.

Molecular Therapy: Oncolytics, Vol. 31 · 2023 · English · DOAJ

A novel GPI-anchored dominant-negative TGF-β receptor II renders T cells unresponsive to TGF-β signaling

Sven H. Petersen; Kays Al Badawy; Richard Hopkins et al.

Molecular Therapy: Oncolytics, Vol. 31 · 2023 · English · DOAJ

Transforming growth factor β (TGF-β) is a pleiotropic cytokine expressed by a wide range of cell types and is known for hampering the effectiveness of cancer immune cell therapeutic approaches. We have designed a novel construct containing the extracellular domain of the TGF-β receptor II linked to…

A library of cancer testis specific T cell receptors for T cell receptor gene therapy

Marije A.J. de Rooij; Dennis F.G. Remst; Dirk M. van der Steen et al.

Molecular Therapy: Oncolytics, Vol. 31 · 2023 · English · DOAJ

PTEN potentiation of oncolytic HSV therapy for glioblastoma

Christian Migliarese; Hiroaki Wakimoto

Molecular Therapy: Oncolytics, Vol. 29 · 2023 · English · DOAJ

Trap and ambush therapy using sequential primary and tumor escape-selective oncolytic viruses

Mason J. Webb; Timothy Kottke; Benjamin L. Kendall et al.

Molecular Therapy: Oncolytics, Vol. 29 · 2023 · English · DOAJ

In multiple models of oncolytic virotherapy, it is common to see an early anti-tumor response followed by recurrence. We have previously shown that frontline treatment with oncolytic VSV-IFN-β induces APOBEC proteins, promoting the selection of specific mutations that allow tumor escape. Of these…

Triple combination therapy for pancreatic cancer remodels stroma and improves survival

Karina Vázquez-Arreguín; Balveen Kaur

Molecular Therapy: Oncolytics, Vol. 29 · 2023 · English · DOAJ

Neoadjuvant use of oncolytic herpes virus G47Δ prevents local recurrence after insufficient resection in tongue cancer models

Kosuke Inoue; Hirotaka Ito; Miwako Iwai et al.

Molecular Therapy: Oncolytics, Vol. 30 · 2023 · English · DOAJ

A complete resection of tongue cancer is often difficult. We investigate the usefulness of administering G47Δ (teserpaturev), a triple-mutated oncolytic herpes simplex virus type 1, prior to resection. G47Δ exhibits good cytopathic effects and replication capabilities in all head and neck cancer…

CM082 Enhances the Efficacy of Chemotherapeutic Drugs by Inhibiting the Drug Efflux Function of ABCG2

Lejia Xu; Jiwei Huang; Jie Liu et al.

Molecular Therapy: Oncolytics, Vol. 31 · 2023 · English · DOAJ